Epigenomics Ag

Therawis Diagnostics Gmbh

Sabine Maier

Ralf Lesche

Manfred Schmitt

Nadia Harbeck

Peter Adorjan

John Foekens

John W Martens

Heinz Hoefler

Fabian Model

Susan Cottrell

Thomas Koenig

Matthias Burger

Inko Nimmrich

Almuth Marx

Dimo Dietrich

Thomas Hildmann

Oliver Hartmann

Antje Kluth Lukas

Armin Schmitt

Theo De Vos

Tamas Rujan

Achim Plum

Serenella Eppenberger-Castori

Suzanne Mooney

Vincent Vuaroqueaux

Volkmar Mueller

Frederique Spyratos

Ina Schwope

Maxime P Look

Gunter Weiss

Frédérique Spyratos

Heinz Höfler

John Martens

The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.

Markers for the prediction of outcome of anthracycline treatment

Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.

Method and nucleic acids for the analysis of colon cell proliferative disorders

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Methods for the prognosis of breast cancer

The invention provides methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders as well as therapy thereof by analysis of the gene EYA4 and its promoter and regulatory sequences. The invention further provides novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said gene as well as methods, assays and kits thereof.

Method and nucleic acids for the analysis of colorectal cell proliferative disorders

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.

Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy

Growing community of inventors

Brussels, Belgium

Sabine Maier